Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009
Monday December 21, 2009, 8:00 am EST
BEIJING, Dec. 21 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac was selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009. The honor was given to Sinovac at the 2009 China Business Annual Meeting on Enterprise Competitiveness.
The "Competitiveness Measure" is the measuring model developed by the experts from the Research Center of Chinese Industries and Enterprise Competitiveness and China Business Media. The model evaluates the competitiveness of Chinese listed companies through the criteria including the listed companies' sales revenue, net assets, net profits, the sales revenue, growth rate of net profits, and return on net assets in the past three years. The evaluation result will become an objective and authoritative reference for management and investors.
Sinovac, an independent company publicly traded on the NASDAQ Global Market, shares a position on the list with some of China's large "State-owned Enterprises" such as China National Offshore Oil, PetroChina, China Mobile (Hong Kong), China Unicom, and China Petroleum & Chemical. Completing the Top 10 list are Yingli Green Energy Holdings Co., Ltd., Gushan Environmental Energy Limited, LDK Solar Co., Ltd., and Changzhou Trina Solar Energy Co., Ltd.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We would like to thank China Business and the Institute of Industrial Economics of the Chinese Academy of Social Sciences for bestowing this designation on our Company as it recognizes our collective and successful efforts to develop and commercialize vaccines within a competitive marketplace."
The Annual Meeting on Enterprise Competitiveness has been held since 2003 and is China's only economic forum combining theoretical research and economic practice. The key contents of the annual meeting include: issuing the research results of the Institute of Industrial Economics of the Chinese Academy of Social Sciences and China Business Media; releasing survey results on the competitiveness of listed Chinese enterprises based on analysis of annual report data; and inviting well-known entrepreneurs, economists, and governmental officials to discuss the hottest economic issues for the current year.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccine.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.
EN
